Together we are beating cancer

Donate now

Scientists discover ‘protector of the genome’

The Cancer Research UK logo
by Cancer Research UK | News

17 October 2008

0 comments 0 comments

CANCER RESEARCH UK scientists have discovered a crucial protein called RTEL1 that stops cells from becoming vulnerable to developing cancer, according to research published today (Thursday) in Cell*.

Scientists at the charity’s London Research Institute Clare Hall Laboratories, have for the first time, shown that RTEL1** plays an important role in protecting our cells from DNA rearrangements arising from incorrect DNA repair events, which can lead to the onset of cancer. These findings could result in the protein becoming a target for future cancer treatments.

Lead author Dr Simon Boulton, head of the London Research Institute’s DNA damage response laboratory said: “Studies in yeast have previously identified the Srs2 protein as a critical regulator of DNA repair events essential for maintaining chromosome integrity. Despite 30 years of research an equivalent of Srs2 in humans has remained elusive. We used a microscopic worm to identify a protein, RTEL1, which possesses many of the properties of Srs2. We then looked at human RTEL1 and found that it acted in the same way, which is extremely exciting.”

The scientists went on to find that when the RTEL1 protein was isolated from human cells, it was able to counteract DNA repair events in a test tube, revealing the mechanism through which it is able to prevent inappropriate DNA repair events.

Dr Boulton added: “RTEL1 is fundamentally important in ensuring that DNA damage is repaired correctly, preventing DNA rearrangements. We think this finding will have important implications for understanding cancer as RTEL1 is amplified in certain human tumours.”

Dr Lesley Walker, Cancer Research UK’s director of cancer information said: “Establishing RTEL1’s role in human cells, allows us to start to think about how we might protect cells from DNA damage that is caused when this protein is amplified. This opens up the possibility for new avenues of drug development in the future which is very encouraging.”

ENDS

For media enquiries, please contact the Cancer Research UK press office on 020 7061 8300 or, out of hours, the duty press officer on 07050 264 059.